HIF1A and neoplasm: The combination of metronomic topotecan and pazopanib significantly improved antitumor activity compared to monotherapy with both drugs, and prolonged survival, even in the context of advanced metastatic cancer, with important changes in tumor angiogenesis, tumor cell proliferation, apoptosis, HIF1α levels, and HIF-1 target gene expression [11].